GlassScriptPhysician profile
Alexandra Aarons
NPI 1417342361
$3,357.92
in general payments reported to CMS, 2019-2025
26 companies · $954 in 2025
The $954 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $159 · 2020: $80.00 · 2021: $69.47 · 2022: $265 · 2023: $987 · 2024: $842 · 2025: $954.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,784.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,783.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $680.79 | 2022-2025 | Ubrelvy, Qulipta, Vraylar |
| Novo Nordisk INC | $672.12 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $407.79 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Glaxosmithkline, LLC. | $336.79 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $213.07 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $187.60 | 2023 | Xarelto, Spravato |
| Astrazeneca Pharmaceuticals LP | $118.76 | 2019-2025 | Airsupra, Farxiga |
| Amgen INC. | $118.21 | 2023-2025 | Repatha, Otezla, Otezla |
| Indivior INC. | $106.19 | 2023-2025 | Sublocade |
| Axsome Therapeutics, INC. | $64.18 | 2023-2024 | Auvelity |
| Dexcom, INC. | $60.27 | 2023-2024 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.15 | 2019-2024 | Jardiance |
| Astellas Pharma US INC | $47.84 | 2024 | Veozah |
| Idorsia Pharmaceuticals US INC | $40.79 | 2023 | Quviviq |
| Exact Sciences Corporation | $33.06 | 2025 | Cologuard Collection Kit |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $22.72 | 2025 | General - Pain Management |
| Amneal Pharmaceuticals LLC | $22.26 | 2023 | Unithroid |
| Abbott Laboratories | $21.89 | 2025 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $21.57 | 2023 | Verquvo, Belsomra |
| Otsuka America Pharmaceutical, INC. | $21.27 | 2025 | Abilify Maintena |
| Phathom Pharmaceuticals, INC. | $19.93 | 2025 | Voquezna |
| Biohaven Pharmaceuticals, INC. | $19.44 | 2021 | |
| Sanofi-Aventis U.S. LLC | $17.66 | 2021 | |
| Currax Pharmaceuticals LLC | $14.78 | 2023 | Onzetra Xsail, Contrave |
| E.R. Squibb & Sons, L.L.C. | $14.54 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $14.25 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexandra Aarons listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.